Veracyte Company Profile (NASDAQ:VCYT)

About Veracyte (NASDAQ:VCYT)

Veracyte logoVeracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VCYT
  • CUSIP: N/A
  • Web:
  • Market Cap: $301.65 million
  • Outstanding Shares: 33,893,000
Average Prices:
  • 50 Day Moving Avg: $8.49
  • 200 Day Moving Avg: $8.22
  • 52 Week Range: $5.82 - $9.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.34
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $71.7 million
  • Price / Sales: 4.21
  • Book Value: $1.41 per share
  • Price / Book: 6.31
  • EBITDA: ($20,100,000.00)
  • Net Margins: -35.64%
  • Return on Equity: -53.58%
  • Return on Assets: -29.07%
  • Debt-to-Equity Ratio: 0.53%
  • Current Ratio: 5.83%
  • Quick Ratio: 5.52%
  • Average Volume: 105,664 shs.
  • Beta: 1.92
  • Short Ratio: 9.73

Frequently Asked Questions for Veracyte (NASDAQ:VCYT)

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its earnings results on Monday, July, 31st. The company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.03. The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $18.32 million. Veracyte had a negative net margin of 35.64% and a negative return on equity of 53.58%. The company's revenue was up 25.2% on a year-over-year basis. During the same period last year, the firm posted ($0.40) EPS. View Veracyte's Earnings History.

When will Veracyte make its next earnings announcement?

Veracyte is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Veracyte.

Where is Veracyte's stock going? Where will Veracyte's stock price be in 2017?

6 brokers have issued 12-month target prices for Veracyte's shares. Their forecasts range from $12.00 to $15.00. On average, they expect Veracyte's share price to reach $13.25 in the next year. View Analyst Ratings for Veracyte.

What are analysts saying about Veracyte stock?

Here are some recent quotes from research analysts about Veracyte stock:

  • 1. According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (10/12/2017)
  • 2. Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)

Who are some of Veracyte's key competitors?

Who are Veracyte's key executives?

Veracyte's management team includes the folowing people:

  • Bonnie H. Anderson, Chairman of the Board, Chief Executive Officer
  • Christopher M. Hall, President, Chief Operating Officer
  • Keith S. Kennedy, Chief Financial Officer
  • Julie A. Brooks, General Counsel, Secretary
  • John W. Hanna, Chief Commercial Officer
  • John L. Bishop, Lead Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director
  • Karin Eastham CPA, Independent Director
  • Robert S. Epstein M.D., Independent Director
  • Kevin K. Gordon, Independent Director

How do I buy Veracyte stock?

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veracyte's stock price today?

One share of Veracyte stock can currently be purchased for approximately $8.90.

MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Veracyte (NASDAQ:VCYT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.25 (48.88% upside)
Consensus Price Target History for Veracyte (NASDAQ:VCYT)
Price Target History for Veracyte (NASDAQ:VCYT)
Analysts' Ratings History for Veracyte (NASDAQ:VCYT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/31/2017BTIG ResearchReiterated RatingBuy -> Buy$13.00HighView Rating Details
6/28/2017Janney Montgomery ScottReiterated RatingBuy$15.00LowView Rating Details
5/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
11/22/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
10/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
11/19/2015StephensReiterated RatingBuyN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Veracyte (NASDAQ:VCYT)
Earnings by Quarter for Veracyte (NASDAQ:VCYT)
Earnings History by Quarter for Veracyte (NASDAQ VCYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.22)N/AView Earnings Details
7/31/2017Q2 2017($0.25)($0.22)$18.32 million$18.40 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.24)($0.24)$18.09 million$16.43 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.14)$17.49 million$18.30 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Veracyte (NASDAQ:VCYT)
2017 EPS Consensus Estimate: ($0.92)
2018 EPS Consensus Estimate: ($0.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20172($0.27)($0.26)($0.27)
Q3 20171($0.23)($0.23)($0.23)
Q4 20172($0.22)($0.19)($0.21)
Q1 20182($0.19)($0.18)($0.19)
Q2 20182($0.17)($0.15)($0.16)
Q3 20182($0.14)($0.14)($0.14)
Q4 20182($0.13)($0.11)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Veracyte (NASDAQ:VCYT)
Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 65.67%
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Christopher M HallInsiderSell20,000$9.00$180,000.00View SEC Filing  
9/25/2017Bonnie H AndersonChairmanSell6,000$8.44$50,640.00View SEC Filing  
8/28/2017Evan/ Fa JonesDirectorSell22,500$7.81$175,725.00View SEC Filing  
8/24/2017Evan/ Fa JonesDirectorSell40,000$7.88$315,200.00View SEC Filing  
8/23/2017Evan/ Fa JonesDirectorSell20,000$7.92$158,400.00View SEC Filing  
5/16/2017Jesse I TreuDirectorSell2,226$8.08$17,986.08View SEC Filing  
3/21/2017Bonnie H AndersonChairmanSell5,000$9.09$45,450.00View SEC Filing  
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Veracyte (NASDAQ:VCYT)
Latest Headlines for Veracyte (NASDAQ:VCYT)
DateHeadline logoVeracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting - October 14 at 9:09 AM logoVeracyte, Inc. (VCYT) Downgraded to Sell at Zacks Investment Research - October 12 at 10:22 AM logo Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Quarterly Sales of $19.96 Million - October 11 at 11:54 AM logoVeracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting - October 6 at 12:23 PM logoVeracyte, Inc. (VCYT) Cut to Hold at Zacks Investment Research - October 5 at 11:58 PM logoVeracyte, Inc. (VCYT) Insider Christopher M. Hall Sells 20,000 Shares - October 4 at 8:30 PM logoVeracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA - October 3 at 2:25 PM logoInsider Selling: Veracyte, Inc. (VCYT) Chairman Sells 6,000 Shares of Stock - September 27 at 8:32 PM logoVeracyte, Inc. (VCYT) Given Average Recommendation of "Buy" by Brokerages - September 24 at 8:44 AM logo Brokerages Expect Veracyte, Inc. (VCYT) to Announce -$0.21 EPS - September 20 at 12:30 PM logoVeracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer - September 19 at 9:14 AM logoAwareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together - September 19 at 9:14 AM logoVeracyte to Present at the Cantor Fitzgerald Global Healthcare Conference - September 13 at 10:55 AM logoVeracyte's (VCYT) "Buy" Rating Reaffirmed at Piper Jaffray Companies - September 12 at 5:08 PM logoVeracyte, Inc. (VCYT) Forecasted to Earn Q4 2018 Earnings of ($0.13) Per Share - September 7 at 2:26 PM logoBrokers Offer Predictions for Veracyte, Inc.'s Q1 2018 Earnings (VCYT) - September 6 at 9:29 AM logoVeracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $20.20 Million - September 3 at 1:22 AM logoVeracyte, Inc. (VCYT) Receives New Coverage from Analysts at BTIG Research - August 31 at 7:46 AM logoVeracyte, Inc. (VCYT) Receives Consensus Rating of "Buy" from Brokerages - August 30 at 8:48 AM logoInsider Selling: Veracyte, Inc. (VCYT) Director Sells 22,500 Shares of Stock - August 29 at 8:12 PM logoEvan/ Fa Jones Sells 20,000 Shares of Veracyte, Inc. (VCYT) Stock - August 25 at 8:32 PM logoVeracyte, Inc. (VCYT) Director Sells $315,200.00 in Stock - August 25 at 8:08 PM logoVeracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference - August 25 at 12:13 PM logoVeracyte (VCYT) & DIGILITI MONEY (DGLT) Head-To-Head Comparison - August 20 at 6:18 PM logoETFs with exposure to Veracyte, Inc. : August 17, 2017 - August 18 at 8:28 AM logoVeracyte (VCYT) & Digiliti Money (DGLT) Head-To-Head Contrast - August 16 at 8:34 PM logoAffymetrix (AFFX) & Veracyte (NASDAQ:VCYT) Critical Review - August 11 at 5:10 PM logoContrasting Veracyte (VCYT) and InVitae Corp (NVTA) - August 8 at 12:33 PM logoVeracyte, Inc. (VCYT) Given Average Rating of "Buy" by Analysts - August 5 at 8:44 AM logoVeracyte (NASDAQ:VCYT) and Vermillion (VRML) Financial Survey - August 3 at 10:26 PM logoFY2017 EPS Estimates for Veracyte, Inc. (VCYT) Lifted by Leerink Swann - August 3 at 9:30 AM logoVeracyte, Inc. :VCYT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017 - August 3 at 8:29 AM logoEdited Transcript of VCYT earnings conference call or presentation 31-Jul-17 8:30pm GMT - August 2 at 8:22 AM logoVeracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer - August 1 at 7:27 AM logoInvestor Network: Veracyte Inc. to Host Earnings Call - August 1 at 7:27 AM logoVeracyte Announces Second Quarter 2017 Financial Results - August 1 at 7:27 AM logoVeracyte reports 2Q loss - August 1 at 7:27 AM logoVeracyte, Inc. (VCYT) Issues Quarterly Earnings Results - August 1 at 12:50 AM logoVeracyte (VCYT) and DIGILITI MONEY (DGLT) Financial Review - July 31 at 9:32 AM logoVeracyte (NASDAQ:VCYT) and Vermillion (VRML) Financial Comparison - July 29 at 12:34 PM logo$18.27 Million in Sales Expected for Veracyte, Inc. (NASDAQ:VCYT) This Quarter - July 29 at 7:48 AM logo-$0.25 Earnings Per Share Expected for Veracyte, Inc. (NASDAQ:VCYT) This Quarter - July 27 at 9:03 AM logoVeracyte (VCYT) Says Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer - July 26 at 9:38 AM logoVeracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer - July 26 at 9:38 AM logoVeracyte, Inc. (VCYT) Set to Announce Earnings on Tuesday - July 25 at 7:33 AM logoAnalyzing Veracyte (NASDAQ:VCYT) & CareDx (CDNA) - July 22 at 6:29 PM logoVeracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017 - July 19 at 4:04 PM logoEdited Transcript of VCYT earnings conference call or presentation 1-Mar-17 9:30pm GMT - July 19 at 9:01 AM logoVeracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of "Buy" from Analysts - July 11 at 8:38 AM logoCritical Comparison: Vermillion (VRML) and Veracyte (NASDAQ:VCYT) - July 7 at 8:06 AM



Veracyte (VCYT) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.